The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | Exploring therapy-driven evolution and genetic heterogeneity in CNS lymphomas
James Rubenstein, MD, PhD, University of California San Francisco, San Francisco, CA, discusses genomic aberrations involved in the evolution of central nervous system (CNS) lymphomas, emphasizing how mutations may differ between the onset of disease and progression. He highlights a key finding that tumors associated with lenalidomide or pomalidomide exposure were found to have novel mutations in the Ikaros pathway, which may play a role in resistance to these therapies. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
